Abstract:
The invention relates to serine protease inhibitor compounds of formula (I) where R1 is hydrogen, halo, cyano, nitro or hydroxyl, amino, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, thiol, alkylthio, aminosulphonyl, alkoxyalkyl, alkoxycarbonyl, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl, cycloalkyl, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido, alkylaminosulphonyl, haloalkoxy and haloalkyl; R2 is hydrogen, halo, methyl, amino, hydroxy, or oxo; and R is XnullXnullY(R7)nullLnullLp(D)n; wherein each X independently is a C, N, O or S atom or a CO, CR1, C(R1)2 or NR1 group, at least one X being C, CO, CR1 or a C(R1)2 group; Y (the null-atom) is a nitrogen atom or a CR1 group or Y and L taken together form a cyclic group; R7 is a lipophilic group selected from alkyl, alkenyl, mono- or bi-cycloalkyl, aryl, heteroaryl, mono- or bicycloalkylalkyl, mono- or bicycloalkylalkenyl, aralkyl, heteroaryl-alkyl, arylalkenyl, heteroarylalkenyl all optionally substituted by a group R1; L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; Lp is a lipophilic organic group selected from alkyl, heterocyclic, alkenyl, alkaryl, cycloalkyl, polycycloalkyl, cycloalkenyl, aryl, aralkyl or haloalkyl group or a combination of two or more such groups optionally substituted by one or more of oxa, thia, aza or R1 groups; D is a hydrogen bond donor group; and n is 0, 1 or 2 and salts thereof.
Abstract:
The present invention is directed to a composition containing the reaction product of:(A) a cyclic compound containing a 5, 6, or 7-member ring, the ring containing at least one nitrogen and at least one carbonyl group, at least one carbonyl group being adjacent to at least one said nitrogen;(B) an aldehyde or ketone of 1 to about 15 carbon atoms, or a reactive equivalent thereof; and(C) an etheramine represented by the formulaR.sup.4 (O(CH.sub.2 CH(R)O).sub.n --R.sup.3 --NH.sub.2).sub.y(C-I)wherein in formula (C-I), each n independently is a number from 0 to about 50; each R independently is selected from the group consisting of hydrogen, hydrocarbyl groups of 1 to about 16 carbon atoms, and mixtures thereof; R.sup.3 is selected from the group consisting of hydrocarbylene groups of about 2 to about 18 carbon atoms and groups represented by the formula ##STR1## wherein R.sup.5 and each R.sup.6 are independently hydrocarbylene groups of about 2 to about 10 carbon atoms and p is a number from 1 to about 4; y is 1, 2 or 3; and R.sup.4 is a hydrocarbyl group having a valence of y and containing 1 to about 50 carbon atoms when y is 1, and 1 to about 18 carbon atoms when y is 2 or 3.These compositions are useful as fuel additives for reducing intake valve deposits and advantageously, they do not contribute to an increase in combustion chamber deposits in port fuel injected internal combustion engines. The invention also relates to concentrates and fuel compositions containing the foregoing fuel additive compositions and to a method for reducing intake valve deposits in an internal combustion engine.
Abstract:
A process for preparing trialkylsilyldiazomethanes in which halomethyltrialkylsilane represented by the general formula R.sup.1 R.sup.2 R.sup.3 SiCH.sub.2 X (wherein R.sup.1, R.sup.2 and R.sup.3 denote an alkyl group of 1 to 4 carbon atoms, and X denotes a halogen group) is reacted with metallic magnesium to give a Grignard reagent, which is then reacted with diphenyl phosphoric acid azide.
Abstract translation:制备三烷基甲硅烷基重氮甲烷的方法,其中通式为R 1 R 2 R 3 SiCH 2 X(其中R 1,R 2和R 3表示1至4个碳原子的烷基,X表示卤素基团)表示的卤代甲基三烷基硅烷与金属镁反应,得到格氏试剂, 然后与二苯基磷酸叠氮化物反应。
Abstract:
N-alkoxycarbonyl-substituted cyclic lactams and nitrogen-containing cyclic ketones are prepared by reaction of a C.sub.1-20 alkyl ester of trichloroacetic acid with the corresponding cyclic lactam or nitrogen-containing cyclic ketone.
Abstract:
The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.
Abstract:
The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.
Abstract:
A method produces ε-caprolactam through adipamide as an intermediate, and characteristically includes a lactamization step of reacting adipamide, formed from a material compound, with hydrogen and ammonia in the presence of a catalyst containing: a metal oxide mainly containing an oxide(s) of one or more metallic elements selected from the group consisting of metallic elements of group 5 and groups 7 to 14 in the 4th to 6th periods of the periodic table; and a metal and/or a metal compound having a hydrogenation ability.
Abstract:
The present disclosure relates to novel dinucleotides comprising at least two locked nucleosides, one of which is directly attached to the 3′ end of the triazole linker moiety and the other of which is directly linked to the 5′ end of the triazole linker moiety and that are useful for the preparation of oligonucleotides. The disclosed dinucleotides may be used in gene therapy.
Abstract:
The proteasome inhibitors of this invention include peptide-based compounds with a short linear sequence of amino acids. An oxo or thio group is attached to the N-terminal amino acid. A protein-reactive electrophilic group such as an epoxyketone, an aziridinylketone, or a beta-lactone is attached to the C-terminal amino acid. Upon contact with a proteasome complex in a target cell, the electrophilic group reacts with a functional group in or near a binding pocket or active site of the proteasome, forming a covalent bond and thereby inactivating the proteasome. These and other proteasome inhibitors can be screened for binding affinity and an ability to selectively eliminate senescent cells or cancer cells. Compounds that selectively remove senescent cells can be developed for the treatment of conditions such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis.